Ji Li

Chief Executive Officer at

Feixiang Chemicals (Zhangjiagang) Co., Ltd.

Process Industries

Industrial Services

Health Technology

Profile

Dr. Ji Li is a President & Chief Executive Officer at Ufovax LLC, a Chief Executive Officer at Feixiang Chemicals (Zhangjiagang) Co., Ltd. and a President at Hipro Polymers, Inc. Dr. Li was previously employed as a Chief Executive Officer by Uvax Bio LLC, a Vice President by Solvay Specialty Chemicals Asia Pacific Pte Ltd., and a President by Suzhou HiPro Polymers Co., Ltd.

Ji Li active positions

Companies	Position	Start
Feixiang Chemicals (Zhangjiagang) Co., Ltd. Feixiang Chemicals (Zhangjiagang) Co., Ltd. Chemicals: SpecialtyProcess Industries Produces and distributes fatty specialty chemicals	Chief Executive Officer	2011-01-31
Hipro Polymers, Inc.	President	2011-01-31
Ufovax LLC Ufovax LLC BiotechnologyHealth Technology Operates as biotechnology company which develops vaccines	Chief Executive Officer	2017-12-31

All active positions of Ji Li

Former positions of Ji Li

Companies	Position	End
Uvax Bio, LLC Uvax Bio, LLC Uvax Bio LLC is a biotech pharmaceutical company specializing in the development of next-generation vaccines using its proprietary 1c-sa®pnp platform, which utilizes stable, multi-layered protein nanoparticles to present rationally designed antigens that elicit broad and potent immune responses against infectious diseases. The company is based in Newark, DE. The company’s vaccine pipeline targets major health threats including HIV-1, MERS, pandemic influenza, RSV, HMPV, and Lassa fever. Uvax Bio holds exclusive worldwide rights to the 1c-sa®pnp platform and has an expanding portfolio of clinical and patented preclinical vaccine candidates. The company’s technology enables the production of virus-like protein particles that can display multiple stabilized antigens targeting a wide range of viral and bacterial diseases, produced using a single-step, universal, cell-based manufacturing process. The company was founded in 2018 by Ji Li, Jiang Zhu. Ji Li has been the CEO since 2018.	Chief Executive Officer	2025-02-03
Solvay Specialty Chemicals Asia Pacific Pte Ltd. Solvay Specialty Chemicals Asia Pacific Pte Ltd. Chemicals: SpecialtyProcess Industries Manufactures basic and performance chemicals	Corporate Officer/Principal	-
Suzhou HiPro Polymers Co., Ltd. Suzhou HiPro Polymers Co., Ltd. Oilfield Services/EquipmentIndustrial Services Manufactures and distributes bio-renewable polymades from natural resource cator oil	President	-

See the detail of Ji Li's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ji Li's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
Feixiang Chemicals (Zhangjiagang) Co., Ltd. Feixiang Chemicals (Zhangjiagang) Co., Ltd. Chemicals: SpecialtyProcess Industries Produces and distributes fatty specialty chemicals	Process Industries
Suzhou HiPro Polymers Co., Ltd. Suzhou HiPro Polymers Co., Ltd. Oilfield Services/EquipmentIndustrial Services Manufactures and distributes bio-renewable polymades from natural resource cator oil	Industrial Services
Hipro Polymers, Inc.
Solvay Specialty Chemicals Asia Pacific Pte Ltd. Solvay Specialty Chemicals Asia Pacific Pte Ltd. Chemicals: SpecialtyProcess Industries Manufactures basic and performance chemicals	Process Industries
Ufovax LLC Ufovax LLC BiotechnologyHealth Technology Operates as biotechnology company which develops vaccines	Health Technology
Uvax Bio, LLC Uvax Bio, LLC Uvax Bio LLC is a biotech pharmaceutical company specializing in the development of next-generation vaccines using its proprietary 1c-sa®pnp platform, which utilizes stable, multi-layered protein nanoparticles to present rationally designed antigens that elicit broad and potent immune responses against infectious diseases. The company is based in Newark, DE. The company’s vaccine pipeline targets major health threats including HIV-1, MERS, pandemic influenza, RSV, HMPV, and Lassa fever. Uvax Bio holds exclusive worldwide rights to the 1c-sa®pnp platform and has an expanding portfolio of clinical and patented preclinical vaccine candidates. The company’s technology enables the production of virus-like protein particles that can display multiple stabilized antigens targeting a wide range of viral and bacterial diseases, produced using a single-step, universal, cell-based manufacturing process. The company was founded in 2018 by Ji Li, Jiang Zhu. Ji Li has been the CEO since 2018.

See company connections